TPBG and neoplasm: In xenograft models of HCT-116 cells, both α5T4wt x αCD3low and α5T4v3 x αCD3low exhibited comparable anti-tumor activity (Figure S8) at 0.1 mg/kg, consistent with the similar potencies in CTL assays and similar affinities towards 5T4 by SPR.